S-phase induction by interleukin-6 followed by chemotherapy in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 34, Issue 3-4, 1999, Pages 325-333

  Brown, Peter De Nully ^a   Diamant, Marcus ^a   Jensen, Peter Østrup ^b   Geisler, Christian H ^a   Mortensen, Børge T ^a   Nissen, Nis I ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 6; PREDNISONE; VINCRISTINE SULFATE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL CYCLE S PHASE; CELL LABELING; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DYSPNEA; EPISTAXIS; FATIGUE; HEADACHE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0344994635     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909050957     Document Type: Article

References (31)

1. Callard R. E. & Gearing A. J. H. (1994) The cytokines and their receptors. In The Cytokine FactsBook (Callard R. E. & Gearing A. J. H. Eds), pp. 31-97. Academic Press, London.
2. Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K. & Kishimoto T. (1988) The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 167, 332.
3. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A. & Kishimoto T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332, 83.
4. Klein B., Zhang X. G., Jourdan M., Portier M. & Bataille R. (1990) Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. Curr. Top. Microbiol. Immunol. 166, 23.
5. Heslop H. E., Bianchi A. C., Cordingley F. T., Turner M., Chandima W., De Mel C. P., Hoffbrand A. V. & Brenner M. K. (1990) Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J. Exp. Med. 172, 1729.
6. Biondi A., Rossi V., Bassan R., Barbui T., Bettoni S., Sironi M., Mantovani A. & Rambaldi A. (1989) Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood. 73, 1279.
7. Aderka D., Maor Y., Novick D., Engelmann H., Kahn Y., Levo Y., Wallach D. & Revel M. (1993) Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood. 81, 2076.
8. Van-Kooten C., Rensink I., Aarden L. & van-Oers R. (1993) Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia. 7, 618.
9. Yee C., Biondi A., Wang X. H., Iscove N. N., de Sousa J., Aarden L. A., Wong G. G., Clark S. C., Messner H. A. & Minden M. D. (1989) A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 74, 798.
10. Freeman G. J., Freedman A. S., Rabinowe S. N., Segil J. M., Horowitz J., Rosen K., Whitman J. F. & Nadler L. M. (1989) Interleukin 6 gene expression in normal and neoplastic B cells. J. Clin. Invest. 83, 1512.
11. Maksymiuk A. W., Bratvold J. S., Ezzat W., Tan L. K. & Skinnider L. F. (1994) Non-Hodgkin's lymphoma in Saskatchewan. A review of 10 years' experience. Cancer. 73, 711.
12. Rozman C. & Montserrat E. (1995) Chronic lymphocytic leukemia. N. Engl. J. Med. 333, 1052.
13. Binet J. L. (1993) Treatment of chronic lymphocytic leukaemia. In Chronic lymphocytic leukemia and related disorders (Rozman C. Ed), pp. 867-878. Baillière, London.
14. Catovsky D. & Murphy R. L. (1995) Key issues in the treatment of chronic lymphocytic leukaemia (CLL) [see comments]. Eur. J. Cancer. 31A, 2146.
15. Montillo M., Tedeschi A., Delfini C., Olivieri A., D'Adamo F. & Leoni P. (1995) Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia. Tumori. 81, 419.
16. Carayon P. & Bord A. (1992) Identification of DNA-replicating lymphocyte subsets using a new method to label the bromo-deoxyuridine incorporated into the DNA. J. Immunol. Methods. 147, 225.
17. Mortensen B. T., Schifter S., Pedersen L. B., Jensen A. N., Hovgaard D. & Nissen N. I. (1993) Development and application of a sensitive radioimmunoassay for human granulocytemacrophage colony-stimulating factor able to measure normal concentrations in blood. Exp. Hematol. 21, 1366.
18. Diamant M., Hansen M. B., Rieneck K., Svenson M., Yasukawa K. & Bendtzen K. (1994) Stimulation of the B9 hybridoma cell line by soluble interleukin-6 receptors. J. Immunol. Methods. 173, 229.
19. Drexler H. G., Brenner M. K., Coustan Smith E., Gignac S. M. & Hoffbrand A. V. (1988) Analysis of signal transduction in B chronic lymphocytic leukemia cells. Blood 71, 1461.
20. Jewell A. P., Lydyard P. M., Worman C. P., Giles F. J. & Goldstone A. H. (1995) Growth Factors Can Protect B-Chronic Lymphocytic Leukaemia Cells Against Programmed Cell Death Without Stimulating Proliferation. Leuk. Lymphoma 18, 159.
21. Weber J., Yang J. C., Topalian S. L., Parkinson D. R., Schwartzentruber D. S., Ettinghausen S. E., Gunn H., Mixon A., Kim H., Cole D., Levin R. & Rosenberg S. A. (1993) Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. 11, 499.
22. Gaillard J. P., Bataille R., Brailly H., Zuber C., Yasukawa K., Attal M., Maruo N., Taga T., Kishimoto T. & Klein B. (1993) Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol. 23, 820.
23. Reittie J. E., Yong K. L., Panaytotidis P. & Hoffbrand A. V. (1996) Interleukin-6 Inhibits Apoptosis and Tumour Necrosis Factor Induced Proliferation of B - Chronic Lymphocytic Leukaemia. Leuk. Lymphoma. 22, 83.
24. Weber J., Gunn H., Yang J., Parkinson D., Topalian S., Schwartzentruber D., Ettinghausen S., Levitt D. & Rosenberg S. A. (1994) A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J. Immunother. Emphasis. Tumor. Immunol. 15, 292.
25. van Gameren M. M., Willemse P. H., Mulder N. H., Limburg P. C., Groen H. J., Vellenga E. & de Vries E. G. (1994) Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84, 1434.
26. Veldhuis G. J., Willemse P. H., Sleijfer D. T., van-der-Graaf W. T., Groen H. J., Limburg P. C., Mulder N. H. & de-Vries E. G. (1995) Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J. Clin. Oncol. 13, 2585.
27. Demetri G. D., Bukowski R. M., Samueis B., Gordon M., Antman K., Mehca E. A., Samuel S., Campion M., Levitt D. & Isaacs. R. (1993) Stimulation of Thrombopoiesis by Recombinant Human Interleukin-6 (IL6) Pre- and Post-Chemotherapy in Preiously Untreated Sarcoma Patients with Normal Hematopoiesis. Blood 82 (suppl 1), 367a.
28. Ritch P. S., Schiller J., Rivkin S., Keever C., Witt P. L., Grossbem S. E., Breitmever J. B., Dreclisler D., Truitt R. L., von Hoff D. D. & Borden E. C. (1993) Phase I Evaluation of Recombinant Human Interleukin-6. Blood 82 (suppl 1), 367a.
29. Witzig T. E., Wiseman G., White C. A., Solinger A., Gordon L., Raubitschek A., Emmanoulides C., Royston I., Parker E., Chin P. & Grillo-López A. (1997) IDEC-Y2B8 90Yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma:Interim results of a phase I/II trial. Blood 90 (suppl 1), #2606a.
30. Kaminski M. S., Vose J., Saleh M., Lister T. A., Knox S., Crowther D., Zelenetz A. D., Colcher D. & Wahl R. (1997) A multicenter phase II study of iodine-131 anti-B1 antibody (Bexxar) in patients with Chemotherapy-relapsed/refractory low-grade or transformed low-grade B cell non-Hodgkin's lymphoma. Blood 90 (suppl1), #2268a.
31. Ginaldi L., Martinis M., Matutes E., Faharat N., Morilla R. & Catovsky D. (1997) CD19 and CD20 expression in chronic B cell leukaemias. Blood 90 (suppl 1), #4090B.